(Q36409148)

English

Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

erectile dysfunction

1 reference

based on heuristic

inferred from title

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author name string

Culley C Carson

1

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

publication date

1 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

97 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

39-43; discussion 44-5

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Risk factors for lower urinary tract symptoms in a population-based sample of African-American men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Real life practice in the management of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Sildenafil influences lower urinary tract symptoms.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Cigarette smoking and prostatism: A biphasic association?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06105.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2006.06105.X

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36409148&oldid=1518877284"